Your Psychiatric Medication Isn't Working. Your Genes May Explain Why.

Your CYP2D6 gene encodes an enzyme that sits in your liver and processes one quarter of all medications on the market. For psychiatric drugs especially, it’s the workhorse. Antidepressants like fluoxetine, paroxetine, venlafaxine, and tricyclic antidepressants all depend on CYP2D6 to be cleared from your body. Antipsychotics like haloperidol and risperidone also rely heavily on this enzyme.

Here’s the problem: the CYP2D6 gene comes in dozens of variants (labeled *2, *4, *10, *17, and others), and some people carry duplications of the entire gene. Poor metabolizers, roughly 7 to 10% of people of European ancestry, inherit two non-functional copies. At a standard psychiatric dose, these variants cause drugs to accumulate to toxic levels in your bloodstream. Ultra-rapid metabolizers, who carry gene duplications, burn through medications so fast that they never reach therapeutic levels in the brain.

If you’re a poor metabolizer on a standard dose of fluoxetine or venlafaxine, you may experience severe tremor, confusion, abnormal bleeding, or serotonin syndrome (agitation, rapid heartbeat, fever, muscle rigidity). If you’re ultra-rapid, the medication feels like you’re taking a placebo. Either way, the medication gets blamed. You get labeled treatment-resistant. You switch drugs. The cycle repeats.

CYP2C19 metabolizes a different set of antidepressants than CYP2D6, including citalopram, escitalopram, sertraline, and some tricyclics. It also processes proton pump inhibitors (PPIs) for acid reflux. If you’re on both a psychiatric medication and a PPI, CYP2C19 becomes even more critical because both drugs compete for the same enzyme.

Variants in CYP2C19 (labeled *2, *3 for poor metabolizers and *17 for ultra-rapid) affect roughly 2 to 15% of the population depending on ancestry. Poor metabolizers accumulate antidepressants to levels that trigger suicidal ideation, emotional blunting, or severe sexual dysfunction at standard doses. Ultra-rapid metabolizers never reach therapeutic levels and report no benefit despite months of treatment.

You may have spent a year trying different SSRIs, not realizing the problem was never the specific drug but your genetic inability to process any of them at standard doses. A CYP2C19 test collapses that timeline from months to days.

CYP2C9 doesn’t metabolize psychiatric medications directly, but it matters because roughly 30% of people on antidepressants also take NSAIDs (ibuprofen, naproxen) for pain or inflammation. CYP2C9 also processes warfarin, the blood thinner used after stroke or with certain heart conditions. Psychiatric illness and cardiovascular risk often co-occur, so this gene becomes relevant quickly.

Variants in CYP2C9 (*2, *3) reduce enzyme function, and they’re present in roughly 5 to 10% of people of European ancestry. Poor metabolizers experience toxic NSAID accumulation (GI bleeding, ulcers) or dangerous warfarin levels (bleeding risk) at standard doses. The complication: if you’re also on an antidepressant metabolized by the same liver pathways, you’ve got a traffic jam. Both drugs back up.

You may have developed stomach ulcers or unexplained bruising while on what your doctor considered safe doses of both an antidepressant and an NSAID. Genetic testing explains why your liver couldn’t handle both.

VKORC1 encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K in your body. Warfarin works by blocking this enzyme to prevent blood clots. If you carry the VKORC1 A allele, your enzyme is already slightly less active, which means warfarin hits harder than expected.

Roughly 40% of people of European ancestry carry at least one A allele. If you’re on warfarin and your psychiatrist adds an antidepressant that CYP2C19 doesn’t handle well, your INR (international normalized ratio, a measure of blood thickness) skyrockets, and you face bleeding risk. The gene doesn’t care which enzyme your antidepressant uses; it just means you’re sensitive to warfarin baseline.

If you’ve had an INR spike after starting an antidepressant, or your doctor expressed concern about drug interactions you didn’t understand, VKORC1 testing explains whether genetic sensitivity to warfarin is part of the problem.

SLCO1B1 encodes a transporter that pulls statins (cholesterol-lowering drugs) into your liver cells where they work. If you carry the SLCO1B1 *5 variant (the C allele), this transporter is less efficient. Statins don’t enter liver cells as readily, so they remain circulating in your bloodstream at higher levels.

Roughly 15% of the population carries this variant. High systemic statin levels increase myopathy risk (muscle pain and breakdown) and liver damage, especially in poor metabolizers of the statin itself. Now layer in an antidepressant metabolized by CYP3A4 or CYP2D6 that also competes for liver processing, and you’ve created a situation where both drugs accumulate.

You may have developed muscle pain or weakness attributed to depression or aging, never realizing it was the combination of a statin variant and an antidepressant that couldn’t be cleared efficiently.

TPMT encodes thiopurine methyltransferase, an enzyme that processes thiopurine drugs like azathioprine and 6-mercaptopurine. These are immunosuppressants used for autoimmune conditions (rheumatoid arthritis, Crohn’s disease, lupus), conditions that psychiatric patients carry at higher rates than the general population.

Tpmt poor metabolizers are rare, roughly 0.3% of the population, but when they exist, the consequences are severe. Poor metabolizers accumulate toxic thiopurine metabolites and face life-threatening bone marrow suppression (no white blood cells, no platelets) at standard doses. The risk is so high that thiopurine dosing now routinely includes TPMT testing.

If you’re on both an antidepressant and azathioprine for an autoimmune condition, TPMT becomes immediately relevant. You may have been told to stay on standard doses of both and monitor bloodwork. Genetic testing eliminates the guessing and prevents bone marrow toxicity before it happens.